TScan Therapeutics, Inc.
TCRX
$0.97
$0.1315.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 106.65% | 266.65% | -10.03% | -42.94% | -70.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 106.65% | 266.65% | -10.03% | -42.94% | -70.15% |
| Cost of Revenue | -6.78% | 4.84% | 22.97% | 21.84% | 23.07% |
| Gross Profit | 11.43% | 2.21% | -26.36% | -31.17% | -41.14% |
| SG&A Expenses | -2.09% | 4.30% | 18.29% | 23.22% | 24.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.75% | 4.72% | 21.94% | 22.14% | 23.28% |
| Operating Income | 9.30% | 0.75% | -24.44% | -29.25% | -36.84% |
| Income Before Tax | 5.46% | -1.78% | -28.12% | -30.99% | -35.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.46% | -1.78% | -28.12% | -30.99% | -35.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.46% | -1.78% | -28.12% | -30.99% | -35.83% |
| EBIT | 9.30% | 0.75% | -24.44% | -29.25% | -36.84% |
| EBITDA | 9.07% | -0.18% | -27.03% | -32.32% | -40.42% |
| EPS Basic | 19.20% | 14.87% | -14.51% | -15.53% | -17.97% |
| Normalized Basic EPS | 19.19% | 14.82% | -13.62% | -14.62% | -17.01% |
| EPS Diluted | 19.20% | 14.87% | -14.51% | -15.53% | -17.97% |
| Normalized Diluted EPS | 19.19% | 14.82% | -13.62% | -14.62% | -17.01% |
| Average Basic Shares Outstanding | 38.27% | 42.30% | 12.20% | 13.64% | 15.05% |
| Average Diluted Shares Outstanding | 38.27% | 42.30% | 12.20% | 13.64% | 15.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |